Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

医学 奥曲肽 安慰剂 神经内分泌肿瘤 中期分析 内科学 胃肠病学 肿瘤进展 临床终点 生长抑素 危险系数 原发性肿瘤 安慰剂对照研究 转移 肿瘤科 癌症 随机对照试验 病理 双盲 置信区间 替代医学
作者
Anja Rinke,Hans‐Helge Müller,Carmen Schade‐Brittinger,Klaus‐Jochen Klose,Peter Barth,M. Wied,Christina Mayer,Behnaz Aminossadati,Ulrich‐Frank Pape,Michael Bläker,Jan Harder,Christian Arnold,Thomas M. Gress,R. Arnold
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:27 (28): 4656-4663 被引量:2154
标识
DOI:10.1200/jco.2009.22.8510
摘要

Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. The hypothesis was that octreotide LAR prolongs time to tumor progression and survival.Treatment-naive patients were randomly assigned to either placebo or octreotide LAR 30 mg intramuscularly in monthly intervals until tumor progression or death. The primary efficacy end point was time to tumor progression. Secondary end points were survival time and tumor response. This report is based on 67 tumor progressions and 16 observed deaths in 85 patients at the time of the planned interim analysis.Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072). After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group. Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor. Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively. The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助科研通管家采纳,获得10
刚刚
田様应助科研通管家采纳,获得10
1秒前
LZQ应助科研通管家采纳,获得10
1秒前
NexusExplorer应助科研通管家采纳,获得30
1秒前
在水一方应助科研通管家采纳,获得10
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
酷波er应助科研通管家采纳,获得10
1秒前
Owen应助科研通管家采纳,获得10
1秒前
1秒前
1秒前
无花果应助科研通管家采纳,获得10
1秒前
嗯哼发布了新的文献求助10
2秒前
凳凳子发布了新的文献求助10
2秒前
wjy完成签到,获得积分20
3秒前
柠檬加盐发布了新的文献求助10
3秒前
Kiosta发布了新的文献求助10
3秒前
3秒前
天天快乐应助之_ZH采纳,获得10
3秒前
零零发布了新的文献求助10
3秒前
4秒前
4秒前
panda_123完成签到,获得积分10
4秒前
彭于晏应助欣喜忻采纳,获得10
4秒前
5秒前
蒋瑞雪yuki_完成签到 ,获得积分10
5秒前
6秒前
魁梧的盼雁完成签到,获得积分10
7秒前
7秒前
所所应助Ronee采纳,获得10
7秒前
7秒前
陈谨诺完成签到,获得积分10
8秒前
GoodEnough发布了新的文献求助10
8秒前
852应助端庄的学姐采纳,获得10
8秒前
玛卡巴卡发布了新的文献求助10
9秒前
Kiosta完成签到,获得积分10
9秒前
9秒前
9秒前
Roxy发布了新的文献求助10
10秒前
10秒前
明理采珊发布了新的文献求助10
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976058
求助须知:如何正确求助?哪些是违规求助? 3520294
关于积分的说明 11202245
捐赠科研通 3256804
什么是DOI,文献DOI怎么找? 1798471
邀请新用户注册赠送积分活动 877610
科研通“疑难数据库(出版商)”最低求助积分说明 806496